Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

PDSB Relative to the S&P 500

PDSB Relative to the Sector

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the PDS Biotechnology Corporation (NASD:PDSB) seasonal charts above shows that a Buy Date of April 20 and a Sell Date of August 4 has resulted in a geometric average return of 26.5% above the benchmark rate of the S&P 500 Total Return Index over the past 9 years. This seasonal timeframe has shown positive results compared to the benchmark in 7 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 9 years by an average of 76.65% per year.

The seasonal timeframe is Inline with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

A word of caution: Only 9 years of data is available for shares of PDSB, perhaps insufficient to create a seasonal profile that accurately gauges the seasonal tendencies influencing the investment. Ideally, while 20 years is preferred, at least 10 years of data is required to perform a seasonal analysis that is considered to be reliable for future seasonal periods.

PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is?engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.

To download PDSB seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: PDSB